Pediatric atopic dermatitis (AD) is one of the most common dermatoses encountered by health-care providers treating children. Diagnosis of AD is clinical, with no universally accepted biomarkers or assessment tools. Patient-reported outcomes and subjective assessments of quality of life in both the patient and family are important considerations when treating pediatric AD. Here, we provide an overview of pediatric AD epidemiology, its clinical presentation, burden, diagnosis, and assessment, with a focus on implications for patient counseling in order to optimize care.
Epidemiology
Several groups have sought to determine the true prevalence of pediatric AD, with disparate study designs, sampling methodologies, age groups, and definitions of AD. 8 Despite these challenges, the International Study of Asthma and Allergies in Childhood (ISAAC) cross-sectional population surveys generated some good estimates of AD prevalence for international comparison. 8 One-year prevalence rates worldwide ranged from 2% to 22.3% in children aged 6-7 years 9 ; however, prevalence can vary based on geographical location. In Canada, the estimate was 12% based on a sample from a single city. 9, 10 In an ISAAC study of adolescents in 5 major cities across Canada, prevalence varied from 8.2% to 10.4% between cities. 11 Certain racial and ethnic populations are known to be disproportionately affected by AD. These differences in disease presentation and phenotype seem to correlate not only with genotype, but also with climate, allergen exposure, and/or environmental factors. 12, 13 For example, AD incidence and persistence were found to be higher among certain nonwhite racial/ethnic subgroups in the United States. 13 Non-Hispanic blacks and Hispanics with early childhood AD were more likely to have persistent AD. 13 A recent review of 2 large US cohorts found that genetic measures do not independently explain the higher prevalence of AD in self-identified African Americans. 14 
Based on limited studies, pediatric AD in Latin
American tropical climates appears to be later onset (after 3 years), suggesting a different phenotype in these regions. 15, 16 In Canada, the prevalence of AD in children from Indigenous communities is higher than the prevalence reported in major cities, ranging from 16.5% to 27.6% in Iqaluit and a Native Reserve in Labrador. [17] [18] [19] In addition to racial differences, sociodemographic and economic determinants of health may play a role in AD prevalence, [20] [21] [22] with most studies reporting a correlation between higher socioeconomic status and increased AD prevalence. 23
Clinical Presentation
The most prevalent clinical features of AD are pruritus, lichenification, and xerosis, but clinical presentation varies with age and geography. 12 A recent systematic review and meta-analysis assessing regional and age-related differences found flexural involvement to be less common in countries such as India, the Americas, and Iran, whereas papular lichenoid lesions, palmar hyperlinearity, ichthyosis, and orbital darkening were more common in Africa. 12 Compared to European-American patients, the East Asian AD phenotype combines features of psoriasis and AD, with atypical features including increased hyperplasia, parakeratosis, higher T H 17 activation, and a stronger T H 2 component despite the presence of elevated IgE, suggesting a genetic basis for the varying disease endotypes. 24, 25 As the prevalence of AD decreases with age, the initial, more generalized distribution and greater truncal involvement seen in younger children 21 changes into a more localized, flexural disease in older children. Pediatric AD is also associated with more exudative lesions, seborrhea-like features, and higher involvement of the eyelid, auricular area, and ventral aspect of the wrist than adult AD. 12
Molecular and Diagnostic Features
Diagnostic criteria for AD are not uniform and have been formalized by several groups. The most common diagnostic criteria include Hanifin-Rajka, 26 the UK working group, 27 and the modified AAD criteria, 28, 29 as outlined in Table 1 . Table 1 . Overview of Major Diagnostic Criteria. Hanifin and Rajka (1980) 26, 29, 70 UK Working Party (1994) 27, 29 AAD revision of UK Working Party criteria (2003) 28, 29 Description of criteria Our group considers the AAD criteria 28, 29 to be most practical for clinical use and applicable across different age groups. Multiple studies have underscored the importance of type 2 cytokines, namely IL-4 and IL-13, in the pathogenesis of AD and other diseases of the atopic diathesis, with important implications for the development of targeted therapies. 30, 31 Type 2 inflammation also suppresses the development of protective type 1 immunity to a wide range of pathogens, leading to uncontrolled or persistent infection. 31 Dysbiosis of the skin microbiome is common in AD, predominantly characterized by a relative overrepresentation of Staphylococcus aureus. Importantly, type 2 cytokines have been shown to inhibit the production of antimicrobial peptides that limit S. aureus growth in healthy skin. 32 Moderateto-heavy growth of S. aureus is also associated with increased AD severity and clinical features such as lichenification and excoriation. 33
Burden of Disease
Pediatric AD is associated with significant direct and indirect costs to both individuals and the health-care system. [34] [35] [36] Data from the United States suggests that pediatric AD causes disproportionately higher emotional burden on lower income families. 34 Emergency department visits for both children and adults with AD have increased and are associated with younger patient age, lower household income, and lack of insurance. 37 AD is also associated with loss of productivity, with up to 50% of patients experiencing disruption in school and/or work. 35, 38 AD disrupts normal functioning and activities of daily living, leading to negative psychosocial outcomes. 39 Up to 86% of patients avoid everyday activities because of their disease. 38 A review and synthesis of the qualitative literature provides insights into the psychosocial aspects of pediatric AD, including parents struggling with physical management of the disease and children/adolescents experiencing negative social reactions. 40 In fact, emotional stress experienced by caregivers has been shown to correlate with disease severity. 41, 42 Pediatric AD also has a major impact on the quality of life (QoL) of patients and their families. 43 In Canada, up to 52% of families report impaired QoL when caring for a child with AD. 39 Notably, the QoL impact of pediatric AD has been found to be comparable or higher than that of other chronic conditions including asthma, diabetes mellitus, and cystic fibrosis. 44 In one study, health-related QoL was the same in boys and girls, with girls reporting significantly higher embarrassment on the Children's Dermatology Life Quality Index (CDLQI). 34 Sleep disturbance is a very common symptom of pediatric AD and is a major factor leading to impaired QoL. It affects up to 70% of children with moderate-to-severe AD 39 and up to 83% of children during a flare. 45 Sleep disturbance, including reduced sleep efficiency, longer sleep latency onset, more sleep fragmentation, and less nonrapid eye movement sleep, 46 may perpetuate inflammation and pruritus in AD or vice versa. 47 In addition, up to 61% of caregivers report having disturbed sleep. 39, 48 In one study, parents caring for a child with AD lost a median of 30-45 minutes of sleep per night, with sleep loss correlating with anxiety and depression. 49
Physician Assessment Tools
Many objective tools have been developed to assess the severity and impact of AD. However, few are sufficiently validated and none are practical for clinical use outside of clinical trials. 50 For a brief comparison of relevant physician assessment tools in AD, see Table 2 (modified from Gooderham, 2018) . 50 Although assessment tools such as Eczema Area and Severity Index (EASI) and SCORing Atopic Dermatitis (SCORAD) have been validated and are recommended for use in research, 29, 51 their clinical use, particularly in the pediatric population, is less practical.
A comparison of AD severity scales in a population of 9 children and 3 adults showed that EASI is the most reliable assessment measure, with the highest inter-and intrarater reliability when compared to objective SCORAD (oSCORAD); the Six Area, Six Sign Atopic Dermatitis (SASSAD) severity score; and the Three Item Severity score. 52 Notably, EASI and oSCORAD have shown good interrater and intrarater reliability in patients of all skin colours, with oSCORAD being slightly inferior to EASI. 53 This is contrary to previous studies which demonstrated poor reliability in pigmented skin. 54 Despite the strong performance of EASI in trials, it is more cumbersome to conduct than the Physician Global Assessment (PGA) in clinical practice. PGA, also known as the Investigator Global Assessment (IGA), is considered easier to conduct and more clinically relevant compared to other investigator assessments. 55 The various versions of PGA should be noted, with most versions lacking standardization and validation. 56 Body surface area (BSA) estimation is an important aspect of scoring AD severity; however, it is not straight forward to measure in growing children with changing body proportions. BSA measurement by scoring palms, such as in oSCORAD, may result in over-or underestimation of the affected area, especially in babies and small children. 52 Overall, no specific objective assessment is recommended for routine clinical use in determining AD severity in the pediatric population. HCPs should use their clinical judgment in considering the use of PGA and/or BSA for clinical evaluation and monitoring of treatment response.
Patient-Reported Outcomes
Patient-reported outcomes (PROs) evaluate important aspects of disease impact that are not captured by objective Performed for some scales. 10 At the time of this writing validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) had been validated but results were not yet published.
c Some IGA scales, such as the vIGA-AD, include some notion of BSA involved. 60 It should be noted that subjective symptoms do not always correlate with disease extent or severity. 61 For an abbreviated summary of the most commonly used patient-reported assessment tools in pediatric AD, see Table 3 (modified from Gooderham, 2018) . 50 QoL questionnaires are important PROs that measure burden of disease in AD patients and their families. Those used in pediatric AD include the CDLQI, 62 the Infant's Dermatitis Quality of Life Index (IDQoL), 63 Dermatitis Family Impact (DFI) questionnaire, Family Dermatology Life Quality Index (FDLQI), 43, 64, 65 Childhood Atopic Dermatitis Impact Scale (CADIS), 48, 66 and the Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ). 67 A recent systematic review of RCTs showed that the CDLQI 62 and IDQoL 63 are the most popular patient-and proxy-reported PROs used to assess QoL in children, 68 whereas the DFI and FDLQI are most popular for assessing family QoL. Despite their wide use in clinical trials, no single instrument is recommended over another based on limited validation data. 69 Importantly, PROs should not be used as a substitute for physician assessment.
Our group recommends that, based on physician judgment, BSA and/or PGA may be used for clinical evaluation and monitoring of treatment response where practical, in combination with PROs including POEM and/or ageappropriate QoL indices.
Conclusions
Recognizing the high burden of pediatric AD worldwide, it is important to optimize treatment based on the current understanding of the disease. During assessment and treatment of the disease, HCPs should consider both patient and family QoL impairments. Pediatric patients with AD and their families should be counseled about its chronic, recurrent, pruritic, and inflammatory nature, the involvement of both genetic and environmental factors, and the need for continuous care.
